Business context and reporting period
The supplied filing is Trovagene, Inc.’s unaudited Form 10-Q for the quarter ended June 30, 2012—not a Cardiff Oncology filing. Trovagene described itself as a development-stage molecular diagnostics company developing urine-based nucleic-acid tests. It reported minimal licensing and royalty revenue and no material revenue from commercial diagnostic or biopharmaceutical products.
Financial results and position
| Metric | Three months ended June 30 | Six months ended June 30 |
|---|---|---|
| Revenue | $41,500 (2012); $79,863 (2011) | $75,653 (2012); $168,946 (2011) |
| Research and development | $477,151 (2012); $143,288 (2011) | $814,558 (2012); $401,304 (2011) |
| General and administrative | $809,868 (2012); $584,025 (2011) | $1,636,830 (2012); $1,135,068 (2011) |
| Net loss | $3,426,410 (2012); $449,159 (2011) | $4,589,050 (2012); $1,001,144 (2011) |
| Net loss per common share | $(0.28) (2012); $(0.05) (2011) | $(0.40) (2012); $(0.11) (2011) |
At June 30, cash and cash equivalents were $9.30 million, current assets $9.44 million, current liabilities $1.24 million, working capital $8.20 million, and total assets $9.95 million. Total liabilities were $4.46 million, including $3.23 million of derivative liabilities; the balance sheet lists no conventional debt at that date. Stockholders’ equity was $5.49 million. The filing does not present a separate gross-margin measure.
For the first six months, operating cash use was $2.20 million, investing cash use $141,000, and financing cash provided $10.95 million. Cash increased by $8.60 million from year-end 2011. At August 10, the company reported approximately $8.3 million of cash and approximately $7.9 million of working capital.
Material changes versus comparable periods
- Six-month revenue declined $93,293 year over year: royalty income fell $73,293, primarily following termination of the Sequenom agreement, and license fees fell $20,000 because no new license agreements were entered into.
- Six-month R&D expense more than doubled, increasing $413,254, largely due to CLIA laboratory start-up, additional personnel, supplies, and expanded laboratory facilities.
- Six-month G&A expense rose $501,762, including higher outside services, executive-related costs, bonuses, and share-based compensation; lower legal and accounting fees partly offset the increases.
- Net loss and operating cash use increased substantially. The 2012 loss included a $2.21 million noncash charge from changes in derivative fair value. The May 2012 public offering also led to reclassification of certain warrant liabilities to equity.
- The May offering and full overallotment generated $9.1 million of net proceeds. The company also completed four private placements raising $1.9 million gross. A 1-for-6 reverse stock split took effect May 29; per-share and share information was retrospectively adjusted.
Outlook, risks, contingencies, and unusual items
- Management stated that additional capital would be required within the next year to develop and commercialize product candidates and fund operations at then-current spending levels. Based on projections, management expected cash to cover expenses through July 2013, but said additional funding might not be available on acceptable terms or at all.
- The filing identifies going-concern uncertainty. If financing cannot be obtained, the company may delay, scale back, or discontinue development, seek earlier or less favorable collaborations, or relinquish technology or product rights. Equity financing could dilute shareholders; debt financing could impose restrictive covenants.
- Management cited early-stage development, clinical and regulatory uncertainty, competition, capital-raising needs, and unpredictable development costs and timelines. No formal financial guidance was provided.
- Derivative warrants were valued using significant unobservable inputs and classified as Level 3. Their fair-value changes caused material noncash earnings volatility.
- A MultiGen Diagnostics asset purchase was recorded as a $187,500 CLIA-license intangible, paid in shares. Up to $3.7 million of additional cash and/or stock may be payable upon sales and earnings milestones; the filing assigned the contingent consideration a fair value of zero at acquisition.
- Disclosure controls and procedures were deemed ineffective at June 30 because of weaknesses in the financial closing process. Management said it intended to implement remedial measures; no material change in internal control over financial reporting was reported during the quarter.
- The company reported no material pending legal proceedings and no off-balance-sheet arrangements.
Important facts for investors to verify
- Confirm the issuer: the supplied document names Trovagene, Inc., while the request identifies Cardiff Oncology, Inc.
- Review subsequent cash use, financing activity, and whether the stated cash runway through July 2013 was achieved.
- Assess the recurring revenue outlook following the Sequenom agreement termination and the lack of new license fees.
- Track R&D and G&A spending, CLIA laboratory commercialization progress, and any resulting product revenue.
- Examine warrant terms, derivative-liability valuation assumptions, potential dilution, and the MultiGen milestone obligations.
- Check remediation of the financial-closing control weaknesses and any subsequent disclosure-control findings.